ARTICLE | Clinical News
Phase III results for PhotoCure
April 19, 2001 7:00 AM UTC
PhotoCure (OSE:PHO) said that in a European Phase III study of its Metvix photodynamic therapy (PDT) in 100 patients with nodular basal cell carcinoma (BCC), the cure rate at 3 months for Metvix PDT (...